September 2026 update

iShares Nasdaq US Biotechnology UCITS ETF · IE00BYXG2H39 · BTEC

Rebalix monthly basket snapshots compared: 6 August 2026 → 31 August 2026 (issuer-declared dates; each section states its own)

In brief: 0 holdings added and 0 removed from the basket · large-holding weights nearly unchanged · NAV change over the period +7.0% · costs and key facts unchanged.

Top-ten concentration increased by 2.2 percentage points.

Declared positions

261

260 → 261 · Δ +1

as of 31 Aug

Top-10 weight

44.2%

42.0 → 44.2% · Δ +2.2 p.p.

concentration

NAV change over the period

+7.0%

in USD · 6 Aug → 31 Aug

Assets at month end

1.2 mld $

+8.8% in the month

Basket

Source: basket file published by the issuer, as of 20 Aug and 31 Aug, compared holding by holding by Rebalix (cash excluded, lines of the same holding merged).

Holdings added (0)

None.

Holdings removed (0)

None.

Holdings compared (excluding cash instruments, lines of the same holding merged): 252 → 252, issuer files of 20 Aug and 31 Aug.

Top 10 holdings — before and after

Source: basket file published by the issuer, as of 6 Aug and 31 Aug; snapshots archived by Rebalix on 7 Aug and 2 Sept.

Weight of each holding in the basket at the two snapshots. Together the top 10 weigh 42.0% → 44.2% (Δ +2.2 p.p.). Union of the two top-10 lists: 12 holdings, because 2 entered and 2 left the top 10.

AMGEN INC

8.7%

VERTEX PHARMACEUTICALS

8.3%

GILEAD SCIENCES

7.4%

REGENERON PHARMACEUTICALS

5.3%

MODERNA — enters the top 10

3.6%

REVOLUTION MEDICINES

2.8%

ILLUMINA INC

2.1%

ALNYLAM PHARMACEUTICALS

2.1%

BIOGEN

2.1%

ARGENX SE ADR — enters the top 10

1.8%

INSMED INC — leaves the top 10

1.7%

ROYALTY PHARMA PLC CLASS A — leaves the top 10

1.8%

6 Aug31 Augorange line = up, grey = down; “→” with no value = out of the top 20

See the numbers as a table

Holding	6 Aug	31 Aug
AMGEN INC	8.7%	8.7%
VERTEX PHARMACEUTICALS	7.9%	8.3%
GILEAD SCIENCES	7.1%	7.4%
REGENERON PHARMACEUTICALS	5.5%	5.3%
MODERNA — enters the top 10 (enters top 10)	1.5%	3.6%
REVOLUTION MEDICINES	2.9%	2.8%
ILLUMINA INC	2.0%	2.1%
ALNYLAM PHARMACEUTICALS	2.0%	2.1%
BIOGEN	2.1%	2.1%
ARGENX SE ADR — enters the top 10 (enters top 10)	1.7%	1.8%
INSMED INC — leaves the top 10 (leaves top 10)	2.0%	1.7%
ROYALTY PHARMA PLC CLASS A — leaves the top 10 (leaves top 10)	1.8%	1.8%

Sectors and countries

Source: aggregate breakdowns declared by the issuer in the two snapshots (6 Aug and 31 Aug).

Sectors — where the weight moved

Health Care

99.8 → 99.7% · −0.06 p.p.

Bars scaled to the change: orange = up, grey = down. Basket percentages at the two snapshots.

Countries — the top five

United States

93.2 → 93.0% · −0.17 p.p.

Belgium

1.7 → 1.9% · +0.17 p.p.

Denmark

1.2 → 1.2% · −0.02 p.p.

France

1.2 → 1.1% · −0.12 p.p.

China

0.9 → 0.9% · +0.02 p.p.

Nearly unchanged: every country moves less than ±0.2 points between the two snapshots.

See the numbers as a table

Country	6 Aug	31 Aug
United States	93.2%	93.0%
Belgium	1.7%	1.9%
Denmark	1.2%	1.2%
France	1.2%	1.1%
China	0.9%	0.9%
Germany	0.7%	0.8%
United Kingdom	0.3%	0.3%
Canada	0.1%	0.2%
Netherlands	0.2%	0.2%
Ireland	0.2%	0.1%
Iceland	0.1%	0.1%
Spain	0.1%	0.1%
Australia	0.1%	0.1%
4 more countries below 0.05% in both snapshots

NAV and assets over the period

Source: daily NAV series published by the issuer.

NAV over the period (USD)

6 Aug31 Aug

9.7 → 10.38: +7.0% from 6 Aug to 31 Aug, the last NAV available at each snapshot date.

Assets over the month

3 Aug31 Aug

1.1 mld $ → 1.2 mld $ (issuer’s daily series).

Costs and key facts

Source: issuer KID (costs as of 2 Sept); Rebalix events register.

TER

0.35%

unchanged

Transaction costs (KID)

0.02%

unchanged

Index, name, policy

unchanged

Issuer-declared basket snapshots, compared by Rebalix. Each section states its own dates: the basket comparison uses the issuer file dates; top 10, composition and breakdowns the dates of the two archived snapshots; maturities, ratings and duration the monthly registry snapshots. Weight changes are shown above ±0.25 points (the archive records them from ±0.1). We record the past: nothing on this page is a recommendation.